See the DrugPatentWatch profile for Ustekinumab
Ustekinumab, marketed as Stelara, is a biologic drug used to treat several autoimmune conditions. Its price can vary significantly based on factors such as insurance coverage, dosage, location, and whether it is obtained through a specialty pharmacy or directly from a healthcare provider. As of recent data, the list price for Stelara can range from approximately $6,000 to over $12,000 per dose [1]. This pricing reflects the complex manufacturing processes and research and development costs associated with biologic medications.
How much does a Stelara injection cost?
A single Stelara injection, which is typically administered subcutaneously, can incur costs ranging from $6,000 for a lower dose (e.g., 45 mg) to over $12,000 for a higher dose (e.g., 90 mg) [1]. These figures represent the manufacturer's list price and do not account for potential discounts or patient assistance programs. For patients without adequate insurance, the out-of-pocket expenses can be substantial.
Can I get Stelara at a lower cost?
Patients may be able to access Stelara at a lower cost through various avenues. Manufacturer-sponsored patient assistance programs, such as those offered by Janssen (the manufacturer of Stelara), can help eligible individuals reduce their out-of-pocket expenses [2]. Additionally, some insurance plans may negotiate lower prices with pharmacies or providers. Comparing prices across different pharmacies or inquiring about potential savings with your healthcare provider or insurer is advisable.
When does Stelara's patent expire?
The patent protection for Stelara is a complex landscape, with multiple patents covering different aspects of the drug, including its composition and methods of use. Generally, the primary patents for Stelara have been subject to challenges and are expected to expire in the coming years, paving the way for biosimilar competition [3]. According to DrugPatentWatch.com, significant patent expiries are anticipated, which could lead to market entry of biosimilars [3].
Will biosimilars reduce the cost of ustekinumab?
The introduction of biosimilar versions of ustekinumab is expected to significantly reduce the cost of treatment. Biosimilars are highly similar to their reference biologic drugs and are proven to be as safe and effective. Once biosimilars enter the market, increased competition typically drives down prices for both the originator drug and the biosimilars themselves [4]. This can make biologic therapies more accessible to a wider patient population.
What conditions does Stelara treat?
Stelara is approved for the treatment of several moderate to severe chronic autoimmune diseases. These include plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis [1][5]. Its mechanism of action involves inhibiting the activity of interleukin-12 and -23, cytokines that play a role in inflammation and immune responses associated with these conditions.
Who manufactures Stelara?
Stelara is manufactured by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [1]. Janssen is responsible for the research, development, marketing, and distribution of Stelara globally.
Sources
1. Janssen Pharmaceuticals. Stelara (ustekinumab) Prescribing Information. [Link to official prescribing information if available, otherwise generalize]
2. Janssen CarePath. Patient Assistance Programs. [Link to Janssen CarePath if available]
3. DrugPatentWatch. Ustekinumab Patent Landscape. [https://drugpatentwatch.com/drug/ustekinumab]
4. U.S. Food and Drug Administration. Biosimilar Medical Interventions. [Link to FDA biosimilar information]
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Ustekinumab. [Link to NIAMS information on Ustekinumab]